Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, Qiu S, Pan S, Zheng Y, Cai J, Chen X, Qu S, Lin L, Huang J, Wu H, Lu Y, Wang W, Hu C, He X, Yu Z, Liu X, Xie B, Liu A, Hu G, Jing S, Zhang Q, Guo R, Li Q, Hong J, Jin F, Meng J, Shi J, Wang P, Cui J, Yang K, Zhang X, Li X, Shen L, He Y, Zhai L, Sun X, Ge J, Qing Y, Zong D. Shi Y, et al. Among authors: li j, li x, li q. Lancet Reg Health West Pac. 2022 Oct 10;31:100617. doi: 10.1016/j.lanwpc.2022.100617. eCollection 2023 Feb. Lancet Reg Health West Pac. 2022. PMID: 36879786 Free PMC article.
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, Hu G, Luo Z, Fu Z, Qu S, Feng W, Chen X, Lin S, Zhang W, Li X, Sun Y, Lin Z, Lin Q, Lei F, Long J, Hong J, Huang X, Zeng L, Wang P, He X, Zhang B, Yang Q, Zhang X, Zou J, Fang W, Zhang L. Yang Y, et al. Among authors: li j, li w, li x. Lancet Oncol. 2021 Aug;22(8):1162-1174. doi: 10.1016/S1470-2045(21)00302-8. Epub 2021 Jun 23. Lancet Oncol. 2021. PMID: 34174189 Clinical Trial.
[Survey of Helicobacter pylori levofloxacin and clarithromycin resistance rates and drug resistance genes in Ningxia, 2020-2022].
Du LM, Hu SJ, Chen XM, Deng YY, Yong HL, Shi RC, Liu JG, Cao ZZ, You YJ, Liu YX, Ma SC, Ma LK, Li XF, Li XM, Hou JB, Ye ZC, Sang T, Cao Y, Liu H, Wei XX, Hu AL, Li YL, Gao HJ. Du LM, et al. Among authors: li xf, li yl, li xm. Zhonghua Yi Xue Za Zhi. 2023 Jul 25;103(28):2163-2167. doi: 10.3760/cma.j.cn112137-20230214-00206. Zhonghua Yi Xue Za Zhi. 2023. PMID: 37482728 Chinese.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Toyohara J, Vugts D, Kiss OC, Todde S, Li XG, Liu Z, Yang Z, Gillings N, Cazzola E, Szymanski W, Meulen NV, Reilly R, Taddei C, Schirrmacher R, Li Z, Lagebo YJ, Bentaleb N, Souza Albernaz M, Lapi S, Ramogida C, Mukherjee A, Ajenjo J, Deuther-Conrad W, Bourdeau C. Toyohara J, et al. Among authors: li xg. EJNMMI Radiopharm Chem. 2024 May 16;9(1):42. doi: 10.1186/s41181-024-00268-w. EJNMMI Radiopharm Chem. 2024. PMID: 38753262 Review.
168,098 results
You have reached the last available page of results. Please see the User Guide for more information.